Drug-maker Catalent has agreed a $1.2bn deal to acquire Baltimore-based Paragon Bioservices, according to a report in The Wall Street Journal. The Baltimore, Maryland-based company is expected to record more than $200 million in revenue this year, the Journal said. Catalent, which is based in San Francisco, said it would pay $US1.3bn, or about $2.5bn, for the company, which makes drugs used by more than 100 million Americans. Neither company has confirmed the report.
Drug-maker Catalent has agreed a $1.2bn deal to acquire Baltimore-based Paragon Bioservices, according to a report in The Wall Street Journal. Catalent, which is based in San Francisco, said it would pay $US1.3bn, or about $2.5bn, for the company, which makes drugs used by more than 100 million Americans. Neither company has confirmed the report.